Drug intelligence / Profile preview

lasiodiplodan

Development stage: Preclinical
Administration: Intraperitoneal

Overview

Lasiodiplodan is a fungal exocellular (1→6)-β-d-glucan, a type of polysaccharide, derived from *Lasiodiplodia theobromae* MMPI. It has demonstrated antiproliferative and pro-apoptotic effects in MCF-7 breast cancer cells. Its mechanism of action involves inducing oxidative stress, activating AMP-activated protein kinase (AMPK) and the Forkhead transcription factor FOXO3a. This leads to increased apoptosis and necrosis, upregulation of mRNA expression for p53, p27, and Bax, and increased activity of Bax and caspase-3, while simultaneously decreasing the activity of p70S6K.

Targets

AMPK (Adenosine monophosphate–activated protein kinase)FOXO3 (Forkhead box protein O3)

Beyond the preview

Go deeper on lasiodiplodan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lasiodiplodan.

Explore the full profile